On May 2, 2008, the U.S. Food and Drug Administration (FDA) placed a black box warning on<unk>  due to a number of serious infections associated with the drug. Serious infections and sepsis, including fatalities, have been reported with the use of<unk>  including reactivation of latent tuberculosis and hepatitis B infections.
Etanercept
Adalimumab
Tofacitinib
Belatacept
Abatacept
Belimumab
Teriflunomide
Theralizumab